Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.40 |
| ▸ | ESR1 | P03372 | 7/20 | 0.40 |
| ▸ | ESRRB | O95718 | 2/20 | 0.40 |
| ▸ | ESRRA | P11474 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172746 | 0.82 | NPC1 (0.47) | BACE1ESR2ESR1ESRRBESRRA | |
| SCHEMBL289452 | 0.77 | BACE1 (0.49) | BACE1ESR2ESR1NPC1MTOR | |
| SCHEMBL31302309 | 0.77 | BACE1 (0.49) | BACE1ESR2ESR1NPC1MTOR | |
| SCHEMBL30152425 | 0.76 | EGFR (0.47) | BACE1ESR2ESR1MEN1KMT2A | |
| SCHEMBL2787330 | 0.76 | HSP90AA1 (0.41) | MTORL3MBTL1ALOX15 | |
| SCHEMBL71628 | 0.76 | EGFR (0.47) | BACE1ESR2ESR1MEN1KMT2A | |
| SCHEMBL29661857 | 0.76 | HSP90AA1 (0.41) | MTORL3MBTL1ALOX15 | |
| SCHEMBL27888312 | 0.74 | ALDH1A1 (0.46) | BACE1NPC1MTORTRPA1 | |
| SCHEMBL2602660 | 0.73 | TP53 (0.40) | ESR2ESR1NPC1TRPA1MEN1 | |
| SCHEMBL3677559 | 0.73 | CA14 (0.41) | ESR2ESR1ESRRBESRRAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260218-A | Preparation method of clilboro | 安庆百谊生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115260218-A | Preparation method of clilboro | 安庆百谊生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115260218-A | Preparation method of clilboro | 安庆百谊生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-104788412-B | Aromatic polycyclic carboxylic acid derivatives | 山东轩竹医药科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-104788412-A | Aromatic polycyclic carboxylic acid derivatives | KBP BIOSCIENCES CO LTD | 2015-07-22 | — | — | CN | disclosed |
| US-8952073-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2015-02-10 | — | — | US | disclosed |
| US-20140107166-A1 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130274344-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2013-10-17 | — | — | US | disclosed |
| US-8471073-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20120190898-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | SHADNIA HOOMAN (CA) | 2012-07-26 | — | — | US | disclosed |
| US-8158684-B2 | Estrogenic compounds, process for their production and pharmaceutical uses thereof | UNIVERSITY OF OTTAWA (CA) | 2012-04-17 | — | — | US | disclosed |
| US-20110196045-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20090234024-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | SHADNIA HOOMAN | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196045-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | BACE1 372/4885ESR2 3/4885ESR1 2/4885 |
| US-20140107166-A1 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC1, HDAC5, HDAC11 | BACE1 2561/4885ESR2 4175/4885ESR1 4677/4885 |
| US-20120190898-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | BACE1 372/4885ESR2 3/4885ESR1 2/4885 |
| US-20130274344-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | BACE1 216/4885ESR2 3/4885ESR1 2/4885 |
| US-20090234024-A1 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF | CYP19A1, ESR1, ESR2 | BACE1 372/4885ESR2 3/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.